| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Expected but not Quantified |
|---|
| Creation Date | 2009-01-30 09:59:52 UTC |
|---|
| Update Date | 2021-09-14 15:00:46 UTC |
|---|
| HMDB ID | HMDB0011627 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Farnesylcysteine |
|---|
| Description | In patients with chronic fatigue syndrome (CFS) we found increased IgM levels to S-farnesyl-L-cysteine. S-farnesyl-L-cysteine plays a key role in regulating cell growth, differentiation and apoptosis through RAS protein activity. The latter depends on their anchorage to the inner surface of the plasma membrane, which is promoted by their common carboxy-terminal S-farnesyl-cysteine. The presence of antibodies to S-farnesyl-L-cysteine suggest that RAS functions may have undergone damage by oxidative/nitrosative stress, causing disturbed functional activity in the regulation of cell growth. (PMID 17159817 ). |
|---|
| Structure | CC(C)=CCC\C(C)=C\CC\C(C)=C\CSC[C@H](N)C(O)=O InChI=1S/C18H31NO2S/c1-14(2)7-5-8-15(3)9-6-10-16(4)11-12-22-13-17(19)18(20)21/h7,9,11,17H,5-6,8,10,12-13,19H2,1-4H3,(H,20,21)/b15-9+,16-11+/t17-/m0/s1 |
|---|
| Synonyms | | Value | Source |
|---|
| S-(2E,6E)-Farnesyl-L-cysteine | ChEBI | | S-trans-trans-Farnesylcysteine | Kegg | | (e,e)-L-S-(3,7,11-Trimethyl-2,6,10-dodecatrienyl)-cysteine | HMDB | | S-all-trans-Farnesyl-L-cysteine | HMDB | | S-[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]-L-cysteine | HMDB | | S-[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl]-L-cysteine,(9ci) | HMDB | | S-Farnesyl cysteine | MeSH, HMDB | | S-Farnesylcysteine | MeSH, HMDB |
|
|---|
| Chemical Formula | C18H31NO2S |
|---|
| Average Molecular Weight | 325.509 |
|---|
| Monoisotopic Molecular Weight | 325.207549931 |
|---|
| IUPAC Name | (2R)-2-amino-3-{[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl]sulfanyl}propanoic acid |
|---|
| Traditional Name | S-farnesylcysteine |
|---|
| CAS Registry Number | 68000-92-0 |
|---|
| SMILES | N[C@@H](CSC\C=C(/C)CC\C=C(/C)CCC=C(C)C)C(O)=O |
|---|
| InChI Identifier | InChI=1S/C18H31NO2S/c1-14(2)7-5-8-15(3)9-6-10-16(4)11-12-22-13-17(19)18(20)21/h7,9,11,17H,5-6,8,10,12-13,19H2,1-4H3,(H,20,21)/b15-9+,16-11+/t17-/m0/s1 |
|---|
| InChI Key | SYSLNQMKLROGCL-BCYUYYMPSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as sesquiterpenoids. These are terpenes with three consecutive isoprene units. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Lipids and lipid-like molecules |
|---|
| Class | Prenol lipids |
|---|
| Sub Class | Sesquiterpenoids |
|---|
| Direct Parent | Sesquiterpenoids |
|---|
| Alternative Parents | |
|---|
| Substituents | - Sesquiterpenoid
- Farsesane sesquiterpenoid
- L-cysteine-s-conjugate
- Cysteine or derivatives
- Alpha-amino acid
- Alpha-amino acid or derivatives
- L-alpha-amino acid
- Amino acid or derivatives
- Amino acid
- Dialkylthioether
- Sulfenyl compound
- Thioether
- Carboxylic acid derivative
- Carboxylic acid
- Monocarboxylic acid or derivatives
- Hydrocarbon derivative
- Organosulfur compound
- Organooxygen compound
- Organonitrogen compound
- Primary amine
- Primary aliphatic amine
- Organopnictogen compound
- Organic oxide
- Carbonyl group
- Amine
- Organic oxygen compound
- Organic nitrogen compound
- Aliphatic acyclic compound
|
|---|
| Molecular Framework | Aliphatic acyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | |
|---|
| Role | Not Available |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | Not Available | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | Not Available | Not Available | | LogP | Not Available | Not Available |
|
|---|
| Experimental Chromatographic Properties | Not Available |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 6.79 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 13.9101 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 3.27 minutes | 32390414 | | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 54.5 seconds | 40023050 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 2646.7 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 258.5 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 160.9 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 167.0 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 94.6 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 483.0 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 501.7 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 131.2 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 1179.5 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 503.7 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1045.6 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 393.0 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 315.3 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 294.3 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 298.9 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 8.0 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| Farnesylcysteine,1TMS,isomer #1 | CC(C)=CCC/C(C)=C/CC/C(C)=C/CSC[C@H](N)C(=O)O[Si](C)(C)C | 2515.0 | Semi standard non polar | 33892256 | | Farnesylcysteine,1TMS,isomer #2 | CC(C)=CCC/C(C)=C/CC/C(C)=C/CSC[C@H](N[Si](C)(C)C)C(=O)O | 2581.4 | Semi standard non polar | 33892256 | | Farnesylcysteine,2TMS,isomer #1 | CC(C)=CCC/C(C)=C/CC/C(C)=C/CSC[C@H](N[Si](C)(C)C)C(=O)O[Si](C)(C)C | 2558.6 | Semi standard non polar | 33892256 | | Farnesylcysteine,2TMS,isomer #1 | CC(C)=CCC/C(C)=C/CC/C(C)=C/CSC[C@H](N[Si](C)(C)C)C(=O)O[Si](C)(C)C | 2507.9 | Standard non polar | 33892256 | | Farnesylcysteine,2TMS,isomer #1 | CC(C)=CCC/C(C)=C/CC/C(C)=C/CSC[C@H](N[Si](C)(C)C)C(=O)O[Si](C)(C)C | 2950.6 | Standard polar | 33892256 | | Farnesylcysteine,2TMS,isomer #2 | CC(C)=CCC/C(C)=C/CC/C(C)=C/CSC[C@@H](C(=O)O)N([Si](C)(C)C)[Si](C)(C)C | 2697.5 | Semi standard non polar | 33892256 | | Farnesylcysteine,2TMS,isomer #2 | CC(C)=CCC/C(C)=C/CC/C(C)=C/CSC[C@@H](C(=O)O)N([Si](C)(C)C)[Si](C)(C)C | 2606.7 | Standard non polar | 33892256 | | Farnesylcysteine,2TMS,isomer #2 | CC(C)=CCC/C(C)=C/CC/C(C)=C/CSC[C@@H](C(=O)O)N([Si](C)(C)C)[Si](C)(C)C | 3115.6 | Standard polar | 33892256 | | Farnesylcysteine,3TMS,isomer #1 | CC(C)=CCC/C(C)=C/CC/C(C)=C/CSC[C@@H](C(=O)O[Si](C)(C)C)N([Si](C)(C)C)[Si](C)(C)C | 2651.9 | Semi standard non polar | 33892256 | | Farnesylcysteine,3TMS,isomer #1 | CC(C)=CCC/C(C)=C/CC/C(C)=C/CSC[C@@H](C(=O)O[Si](C)(C)C)N([Si](C)(C)C)[Si](C)(C)C | 2607.0 | Standard non polar | 33892256 | | Farnesylcysteine,3TMS,isomer #1 | CC(C)=CCC/C(C)=C/CC/C(C)=C/CSC[C@@H](C(=O)O[Si](C)(C)C)N([Si](C)(C)C)[Si](C)(C)C | 2753.7 | Standard polar | 33892256 | | Farnesylcysteine,1TBDMS,isomer #1 | CC(C)=CCC/C(C)=C/CC/C(C)=C/CSC[C@H](N)C(=O)O[Si](C)(C)C(C)(C)C | 2755.0 | Semi standard non polar | 33892256 | | Farnesylcysteine,1TBDMS,isomer #2 | CC(C)=CCC/C(C)=C/CC/C(C)=C/CSC[C@H](N[Si](C)(C)C(C)(C)C)C(=O)O | 2796.6 | Semi standard non polar | 33892256 | | Farnesylcysteine,2TBDMS,isomer #1 | CC(C)=CCC/C(C)=C/CC/C(C)=C/CSC[C@H](N[Si](C)(C)C(C)(C)C)C(=O)O[Si](C)(C)C(C)(C)C | 2981.5 | Semi standard non polar | 33892256 | | Farnesylcysteine,2TBDMS,isomer #1 | CC(C)=CCC/C(C)=C/CC/C(C)=C/CSC[C@H](N[Si](C)(C)C(C)(C)C)C(=O)O[Si](C)(C)C(C)(C)C | 2895.1 | Standard non polar | 33892256 | | Farnesylcysteine,2TBDMS,isomer #1 | CC(C)=CCC/C(C)=C/CC/C(C)=C/CSC[C@H](N[Si](C)(C)C(C)(C)C)C(=O)O[Si](C)(C)C(C)(C)C | 3071.8 | Standard polar | 33892256 | | Farnesylcysteine,2TBDMS,isomer #2 | CC(C)=CCC/C(C)=C/CC/C(C)=C/CSC[C@@H](C(=O)O)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 3134.1 | Semi standard non polar | 33892256 | | Farnesylcysteine,2TBDMS,isomer #2 | CC(C)=CCC/C(C)=C/CC/C(C)=C/CSC[C@@H](C(=O)O)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 2942.5 | Standard non polar | 33892256 | | Farnesylcysteine,2TBDMS,isomer #2 | CC(C)=CCC/C(C)=C/CC/C(C)=C/CSC[C@@H](C(=O)O)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 3181.1 | Standard polar | 33892256 | | Farnesylcysteine,3TBDMS,isomer #1 | CC(C)=CCC/C(C)=C/CC/C(C)=C/CSC[C@@H](C(=O)O[Si](C)(C)C(C)(C)C)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 3370.4 | Semi standard non polar | 33892256 | | Farnesylcysteine,3TBDMS,isomer #1 | CC(C)=CCC/C(C)=C/CC/C(C)=C/CSC[C@@H](C(=O)O[Si](C)(C)C(C)(C)C)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 3118.5 | Standard non polar | 33892256 | | Farnesylcysteine,3TBDMS,isomer #1 | CC(C)=CCC/C(C)=C/CC/C(C)=C/CSC[C@@H](C(=O)O[Si](C)(C)C(C)(C)C)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 2965.1 | Standard polar | 33892256 |
|
|---|
| GC-MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted GC-MS | Predicted GC-MS Spectrum - Farnesylcysteine GC-MS (Non-derivatized) - 70eV, Positive | splash10-00mx-9751000000-c75df345d8656012bdf0 | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Farnesylcysteine GC-MS (1 TMS) - 70eV, Positive | splash10-05aa-8954000000-cb16d7122a6e7b9bef6c | 2017-10-06 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Farnesylcysteine GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Farnesylcysteine 10V, Positive-QTOF | splash10-0a7i-5396000000-851334288f8263d03d23 | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Farnesylcysteine 20V, Positive-QTOF | splash10-00dr-9860000000-dba878d9fc5362b67195 | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Farnesylcysteine 40V, Positive-QTOF | splash10-0adl-9510000000-bd3c119811a4e2799abe | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Farnesylcysteine 10V, Negative-QTOF | splash10-00dr-1659000000-855d9d7f127560943e3d | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Farnesylcysteine 20V, Negative-QTOF | splash10-0079-4791000000-842def471e9561591a94 | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Farnesylcysteine 40V, Negative-QTOF | splash10-0fer-9210000000-618508fb705b5020cbb6 | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Farnesylcysteine 10V, Positive-QTOF | splash10-0aba-1951000000-c167818276c3885878f5 | 2021-09-25 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Farnesylcysteine 20V, Positive-QTOF | splash10-0ab9-2910000000-002b04adc9b951f37f54 | 2021-09-25 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Farnesylcysteine 40V, Positive-QTOF | splash10-0c29-9410000000-00bddc91238723c07f72 | 2021-09-25 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Farnesylcysteine 10V, Negative-QTOF | splash10-0079-1193000000-d24d7910416af3a09863 | 2021-09-25 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Farnesylcysteine 20V, Negative-QTOF | splash10-001r-9060000000-023ebf01c668a96e1673 | 2021-09-25 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Farnesylcysteine 40V, Negative-QTOF | splash10-001i-9110000000-d96ba181641b84daf905 | 2021-09-25 | Wishart Lab | View Spectrum |
|
|---|
| General References | - Maes M, Mihaylova I, Leunis JC: Chronic fatigue syndrome is accompanied by an IgM-related immune response directed against neopitopes formed by oxidative or nitrosative damage to lipids and proteins. Neuro Endocrinol Lett. 2006 Oct;27(5):615-21. [PubMed:17159817 ]
- Lamango NS, Charlton CG: Farnesyl-L-cysteine analogs block SAM-induced Parkinson's disease-like symptoms in rats. Pharmacol Biochem Behav. 2000 Aug;66(4):841-9. [PubMed:10973524 ]
- Havel CM, Fisher P, Watson JA: Isopentenoid synthesis in embryonic Drosophila cells: prenylated protein profile and prenyl group usage. Arch Biochem Biophys. 1992 Jun;295(2):410-20. [PubMed:1586169 ]
- Aharonson Z, Gana-Weisz M, Varsano T, Haklai R, Marciano D, Kloog Y: Stringent structural requirements for anti-Ras activity of S-prenyl analogues. Biochim Biophys Acta. 1998 Feb 27;1406(1):40-50. [PubMed:9545527 ]
- Elad G, Paz A, Haklai R, Marciano D, Cox A, Kloog Y: Targeting of K-Ras 4B by S-trans,trans-farnesyl thiosalicylic acid. Biochim Biophys Acta. 1999 Dec 9;1452(3):228-42. [PubMed:10590312 ]
- Volker C, Miller RA, McCleary WR, Rao A, Poenie M, Backer JM, Stock JB: Effects of farnesylcysteine analogs on protein carboxyl methylation and signal transduction. J Biol Chem. 1991 Nov 15;266(32):21515-22. [PubMed:1939182 ]
- Simons K, Toomre D: Lipid rafts and signal transduction. Nat Rev Mol Cell Biol. 2000 Oct;1(1):31-9. [PubMed:11413487 ]
- Watson AD: Thematic review series: systems biology approaches to metabolic and cardiovascular disorders. Lipidomics: a global approach to lipid analysis in biological systems. J Lipid Res. 2006 Oct;47(10):2101-11. Epub 2006 Aug 10. [PubMed:16902246 ]
- Sethi JK, Vidal-Puig AJ: Thematic review series: adipocyte biology. Adipose tissue function and plasticity orchestrate nutritional adaptation. J Lipid Res. 2007 Jun;48(6):1253-62. Epub 2007 Mar 20. [PubMed:17374880 ]
- Lingwood D, Simons K: Lipid rafts as a membrane-organizing principle. Science. 2010 Jan 1;327(5961):46-50. doi: 10.1126/science.1174621. [PubMed:20044567 ]
- Gunstone, Frank D., John L. Harwood, and Albert J. Dijkstra (2007). The lipid handbook with CD-ROM. CRC Press.
|
|---|